Samsung Bioepis in front row as lights near green on Humira biosimilars in Europe
When a UK High Court judge handed down a judgement to clear the route to market for biosimilar versions of the world’s biggest-selling prescription drug on Friday, the impact on the three companies involved was always going to be significant.
For AbbVie (NYSE: ABBV), the US drugmaker seeking to defend its patents relating to Humira (adalimumab), a drug indicated for rheumatoid arthritis, psoriatic arthritis and psoriasis with global turnover of more than $16 billion and daily UK sales of around £1.4 million ($1.8 million), the ruling is undoubtedly damaging.
For Fujifilm Kyowa Kirin Biologics (FKB), the Japanese company preparing to file an application for marketing authorization for FKB327, a Humira biosimilar, it was a big step forward.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze